Anti-interleukin-5 therapy and severe asthma

New England Journal of Medicine

Volumn 360, Issue 24, 2009, Pages 2577-

  Gleich, Gerald J ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 5; MEPOLIZUMAB; MONOCLONAL ANTIBODY;

ASTHMA; DISEASE EXACERBATION; DRUG EFFICACY; EOSINOPHIL; LETTER; NONHUMAN; PRIORITY JOURNAL; SPUTUM ANALYSIS; DRUG ANTAGONISM; EOSINOPHILIA; HUMAN; IMMUNOLOGY; NOTE; PHYSIOLOGY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ASTHMA; EOSINOPHILIA; EOSINOPHILS; HUMANS; INTERLEUKIN-5; RECURRENCE;

EID: 67149087240     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Wenzel SE. Eosinophils in asthma - closing the loop or opening the door? N Engl J Med 2009;360:1026-1028
2. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
3. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651-663